Cabestrillo con incisión simple para la incontinencia urinaria en mujeres
Appendices
Appendix 1. Searches of trials registers and portals
Both of the searches described below were last run on 20 September 2012.
-
ClinicalTrials.gov Used Advanced search with Search terms = tvt‐s OR tvt‐secur OR mini‐arc OR ajust OR needleless OR solyx OR single‐incision sling OR single incision slings OR altis OR miniarc OR TFS OR minisling OR mini‐sling OR minitape OR mini‐tape OR Ophira OR Zippere OR EPILOG OR arc‐to‐arc.
-
WHO ICTRP the same terms were used as were used in ClinicalTrials.gov (listed above). The search string was copied and pasted straight into the search line.
Appendix 2. Search strategies for economic evaluations for the brief economic commentary
We performed additional searches for the Brief Economic Commentary (BECs). These were conducted in MEDLINE(1 January 1946 to March 2017), Embase (1 January 1980 to 2017 Week 12) and NHS EED (1st Quarter 2016). All searches were conducted on 6 April 2017. We used two different search strategies on MEDLINE and EMBASE (OvidSP) and one on NHS EED (OVID). Details of the searches run and the search terms used can be found below. There were no year, publication type or language restrictions applied to the searches.
NHS EED (Ovid) (1st Quarter 2016)
NHS EED was searched using the following search strategy:
1. Urinary incontinence/
2. Urinary incontinence, stress/
3. ((stress$ or mix$ or urg$ or urin$) adj3 incontinen$).tw.
4. Colporrhaphy.tw.
5. Colpoperineoplast$.tw.
6. Sling procedure$.tw.
7. Sling$ procedure$.tw.
8. Bladder neck needle suspension$.tw.
9. Anterior vaginal repair$ .tw.
10. Or/1‐9
MEDLINE (1 January 1946 to March 2017) and Embase (1 January 1980 to 2017 Week 12)
We used two different search strategies on MEDLINE and EMBASE (OvidSP) ‐ these are given below.
Search strategy 1:
1. Economics, Pharmaceutical/ or Economics, Medical/ or Economics/ or Economics, Hospital/ or economics.mp. or Economics, Nursing/
2. exp "costs and cost analysis"/
3. "Value of Life"/
4. exp "fees and charges"/
5. exp budgets/
6. budget*.ti,ab.
7. cost*.ti.
8. (economic* or pharmaco?economic*).ti.
9. (price* or pricing*).ti,ab.
10. (cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
11. (financ* or fee or fees).ti,ab.
12. (value adj2 (money or monetary)).ti,ab.
13. ((energy or oxygen) adj cost).ti,ab.
14. (metabolic adj cost).ti,ab.
15. ((energy or oxygen) adj expenditure).ti,ab.
16. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15
17. exp Urinary Incontinence/
18. ((stress* or mix* or urg* or urin*) adj3 incontinen*).tw.
19. Urodynamics/ or Urinary Incontinence, Stress/ or Urinary Incontinence/ or Suburethral Slings/ or mixed incontinence.mp. or Urinary Bladder/ or Urinary Incontinence, Urge/
20. 17 or 18 or 19
21. anterior vaginal repair*.tw.
22. 16 and 20 and 21
23. anterior colporrhaphy*.tw.
24. 21 or 23
25. 16 and 20 and 23
26. bladder neck needle suspension$.tw.
27. 16 and 20
28. 26 and 27
29. open abdominal retropubic colposuspension*.tw.
30. retropubic colposuspension*.tw.
31. burch colposuspension*.tw.
32. 29 or 30 or 31
33. 27 and 32
34. laparoscopic retropubic colposuspension*.tw.
35. laparoscopic colposuspension*.tw.
36. 34 or 35
37. 27 and 36
38. traditional suburethral retropubic sling procedure$*.tw.
39. traditional sling procedure$*.tw.
40. suburethral retropubic sling procedure$*.tw.
41. retropubic sling procedure$*.tw.
42. traditional suburethral sling*.tw.
43. Suburethral Slings/ or Urinary Incontinence, Stress/ or Urologic Surgical Procedures/
44. 27 and 43
45. remove duplicates from 44
Search strategy 2:
1. economics.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, sy, tn, dm, mf, dv, kw, fs]
2. value of life.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, sy, tn, dm, mf, dv, kw, fs]
3. exp "costs and cost analysis"/
4. exp economics, hospital/
5. exp economics, medical/
6. economics, nursing.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, sy, tn, dm, mf, dv, kw, fs]
7. economics, pharmaceutical.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, sy, tn, dm, mf, dv, kw, fs]
8. exp "fees and charges"/
9. exp budgets/
10. budget*.ti,ab.
11. cost*.ti.
12. (economic* or pharmaco?economic*).ti.
13. (price* or pricing*).ti,ab.
14. (cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
15. (financ* or fee or fees).ti,ab.
16. (value adj2 (money or monetary)).ti,ab.
17. or/1‐16
18. economics.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, sy, tn, dm, mf, dv, kw, fs]
19. value of life.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, sy, tn, dm, mf, dv, kw, fs]
20. exp "costs and cost analysis"/
21. exp economics, hospital/
22. exp economics, medical/
23. economics, nursing.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, sy, tn, dm, mf, dv, kw, fs]
24. economics, pharmaceutical.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, sy, tn, dm, mf, dv, kw, fs
25. exp "fees and charges"/
26. exp budgets/
27. budget*.ti,ab.
28. cost*.ti.
29. (economic* or pharmaco?economic*).ti.
30. (price* or pricing*).ti,ab.
31. (cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
32. (financ* or fee or fees).ti,ab.
33. (value adj2 (money or monetary)).ti,ab.
34. 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33
35. ((energy or oxygen) adj cost).ti,ab.
36. (metabolic adj cost).ti,ab.
37. ((energy or oxygen) adj expenditure).ti,ab.
38. 34 or 35 or 36 or 37
39. urinary incontinence.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
40. ((stress$ or mix$ or urg$ or urin$) adj3 incontinen$).tw.
41. URINARY INCONTINENCE, STRESS.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
42. stress urinary incontinence*.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
43. 39 or 40 or 41 or 42
44. intervention surgery*.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
45. colporrhaphy.tw.
46. Bologna procedure*.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
47. Kelly‐Kennedy.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
48. Marion Kelly.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
49. Diaphragmplasty.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
50. Vaginal urethrocystopexy.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
51. Cystocele repair.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
52. Kelly plication.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
53. anterior vaginal repair$.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
54. anterior colporrhaphy.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
55. 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54
56. 38 and 43 and 55
57. remove duplicates from 56
58. Bladder neck needle suspension$.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
59. 38 and 43 and 58
60. burch colposuspension.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
61. open abdominal retropubic colposuspension.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
62. Paravaginal defect repair.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
63. Marshall‐Marchetti‐Krantz.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
64. abdominal burch.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
65. abdominal colposuspension.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
66. endopelvic Fascia Plication.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
67. 60 or 61 or 62 or 63 or 64 or 65 or 66
68. 38 and 43
69. 67 and 68
70. laparoscopic retropubic colposuspension.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
71. laparoscopic colposuspension.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
72. retropubic colposuspension.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
73. 70 or 71 or 72
74. 68 and 73
75. remove duplicates from 74
76. suburethral sling.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
77. abdominal sling.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
78. traditional sling procedure$*.tw.
79. suburethral sling procedure.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
80. 76 or 77 or 78 or 79
81. 68 and 80
82. remove duplicates from 81
83. mid$urethral sling.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
84. retropubic sling procedure$*.tw.
85. transobturator sling procedure$.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
86. 83 or 84 or 85
87. remove duplicates from 86
88. 68 and 87
89. TVT‐Secur.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
90. mini‐arc.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
91. ajust.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
92. needleless.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
93. solyx.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
94. single$incision sling$.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
95. miniarc.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
96. mini$sling.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
97. Ophira.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
98. Tissue Fixation System.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
99. 89 or 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98
100. 68 and 99
101. remove duplicates from 100
102. ((urethra$ or periurethra$ or transurethra$) adj3 (agent$ or bulk$ or injection$ or injectable$)).tw.
103. injection therapy.tw.
104. injectable$.tw.
105. (injectable$ adj2 agent$).tw.
106. (bulk$ adj3 agent$).tw.
107. Peri$urethral injection$.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
108. Autologous fat.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
109. Macroplastique.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
110. Calcium hydroxylapatite.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
111. Hyaluronic acid with dextranomer.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
112. Porcine dermal implant.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
113. Ethylene vinyl alcohol copolymer.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
114. Silicon particles.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, eu, pm, sy, tn, dm, mf, dv, kw, fs]
115. 102 or 103 or 104 or 105 or 106 or 107 or 108 or 109 or 110 or 111 or 112 or 113 or 114
116. 68 and 115
117. remove duplicates from 116
PRISMA study flow diagram.
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Comparison 6 Single‐incision sling versus retropubic minimally invasive slings, Outcome 1 Number of women with urinary incontinence.
Comparison 6 Single‐incision sling versus retropubic minimally invasive slings, Outcome 2 Number of women with no improvement.
Comparison 6 Single‐incision sling versus retropubic minimally invasive slings, Outcome 3 Objectve measurement of incontinence.
Comparison 6 Single‐incision sling versus retropubic minimally invasive slings, Outcome 4 Condition‐specific health measures.
Comparison 6 Single‐incision sling versus retropubic minimally invasive slings, Outcome 5 Duration of operation (in minutes).
Comparison 6 Single‐incision sling versus retropubic minimally invasive slings, Outcome 6 Operative blood loss.
Comparison 6 Single‐incision sling versus retropubic minimally invasive slings, Outcome 7 Length of in‐patient stay.
Comparison 6 Single‐incision sling versus retropubic minimally invasive slings, Outcome 8 Major vascular or visceral injury.
Comparison 6 Single‐incision sling versus retropubic minimally invasive slings, Outcome 9 Vaginal wall perforation.
Comparison 6 Single‐incision sling versus retropubic minimally invasive slings, Outcome 10 Bladder or urethral perforation.
Comparison 6 Single‐incision sling versus retropubic minimally invasive slings, Outcome 11 Urinary retention and need for catheterisation.
Comparison 6 Single‐incision sling versus retropubic minimally invasive slings, Outcome 12 Infection related to use of synthetic mesh.
Comparison 6 Single‐incision sling versus retropubic minimally invasive slings, Outcome 13 Vaginal mesh exposure.
Comparison 6 Single‐incision sling versus retropubic minimally invasive slings, Outcome 14 Mesh extrusion into the bladder or urethra.
Comparison 6 Single‐incision sling versus retropubic minimally invasive slings, Outcome 15 Long‐term pain or discomfort.
Comparison 6 Single‐incision sling versus retropubic minimally invasive slings, Outcome 16 Dyspareunia.
Comparison 6 Single‐incision sling versus retropubic minimally invasive slings, Outcome 17 De novo urgency.
Comparison 6 Single‐incision sling versus retropubic minimally invasive slings, Outcome 18 New‐onset detrusor overactivity.
Comparison 6 Single‐incision sling versus retropubic minimally invasive slings, Outcome 19 Repeat stress incontinence surgery.
Comparison 6 Single‐incision sling versus retropubic minimally invasive slings, Outcome 20 Need for any other additional or new surgical procedure to treat complications.
Comparison 7 Single‐incision sling versus obturator minimally invasive slings, Outcome 1 Number of women with urinary incontinence.
Comparison 7 Single‐incision sling versus obturator minimally invasive slings, Outcome 2 Number of women with no improvement.
Comparison 7 Single‐incision sling versus obturator minimally invasive slings, Outcome 3 Objective measurement of incontinence.
Comparison 7 Single‐incision sling versus obturator minimally invasive slings, Outcome 4 Incontinence episodes.
Comparison 7 Single‐incision sling versus obturator minimally invasive slings, Outcome 5 Pad test (weights).
Comparison 7 Single‐incision sling versus obturator minimally invasive slings, Outcome 6 Condition‐specific health measures.
Comparison 7 Single‐incision sling versus obturator minimally invasive slings, Outcome 7 Duration of operation (minutes).
Comparison 7 Single‐incision sling versus obturator minimally invasive slings, Outcome 8 Operative blood loss (mL).
Comparison 7 Single‐incision sling versus obturator minimally invasive slings, Outcome 9 Length of in‐patient stay.
Comparison 7 Single‐incision sling versus obturator minimally invasive slings, Outcome 10 Major vascular or visceral injury.
Comparison 7 Single‐incision sling versus obturator minimally invasive slings, Outcome 11 Bladder or urethral perforation.
Comparison 7 Single‐incision sling versus obturator minimally invasive slings, Outcome 12 Vaginal wall perforation.
Comparison 7 Single‐incision sling versus obturator minimally invasive slings, Outcome 13 Urinary retention and need for catheterisation.
Comparison 7 Single‐incision sling versus obturator minimally invasive slings, Outcome 14 Infection related to use of synthetic mesh.
Comparison 7 Single‐incision sling versus obturator minimally invasive slings, Outcome 15 Vaginal mesh exposure.
Comparison 7 Single‐incision sling versus obturator minimally invasive slings, Outcome 16 Mesh extrusion into the bladder or urethra.
Comparison 7 Single‐incision sling versus obturator minimally invasive slings, Outcome 17 Postoperative pain or discomfort.
Comparison 7 Single‐incision sling versus obturator minimally invasive slings, Outcome 18 Long‐term pain or discomfort.
Comparison 7 Single‐incision sling versus obturator minimally invasive slings, Outcome 19 De novo urgency.
Comparison 7 Single‐incision sling versus obturator minimally invasive slings, Outcome 20 Repeat stress incontinence surgery.
Comparison 7 Single‐incision sling versus obturator minimally invasive slings, Outcome 21 Need for any other additional or new surgical procedure to treat complications.
Comparison 8 One single‐incision sling versus another, Outcome 1 Number of women with urinary incontinence.
Comparison 8 One single‐incision sling versus another, Outcome 2 Number of women with no improvement.
Comparison 8 One single‐incision sling versus another, Outcome 3 Objectve measurement of incontinence.
Comparison 8 One single‐incision sling versus another, Outcome 4 Condition‐specific health measures.
Comparison 8 One single‐incision sling versus another, Outcome 5 Duration of operation (minutes).
Comparison 8 One single‐incision sling versus another, Outcome 6 Operative blood loss.
Comparison 8 One single‐incision sling versus another, Outcome 7 Major vascular or visceral injury.
Comparison 8 One single‐incision sling versus another, Outcome 8 Bladder or urethral perforation.
Comparison 8 One single‐incision sling versus another, Outcome 9 Vaginal wall perforation.
Comparison 8 One single‐incision sling versus another, Outcome 10 Urinary retention and need for catheterisation.
Comparison 8 One single‐incision sling versus another, Outcome 11 Vaginal mesh exposure.
Comparison 8 One single‐incision sling versus another, Outcome 12 Postoperative pain or discomfort.
Comparison 8 One single‐incision sling versus another, Outcome 13 De novo urgency.
Comparison 8 One single‐incision sling versus another, Outcome 14 Repeat stress incontinence surgery.
Comparison 8 One single‐incision sling versus another, Outcome 15 Need for any other additional or new surgical procedure to treat complications.
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
| 1 Number of women with urinary incontinence Show forest plot | 5 | Risk Ratio (M‐H, Random, 95% CI) | Subtotals only | |
| 1.1 Bottom‐up approach | 5 | 573 | Risk Ratio (M‐H, Random, 95% CI) | 2.08 [1.04, 4.14] |
| 2 Number of women with no improvement Show forest plot | 3 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 2.1 Bottom‐up approach | 3 | 246 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.38 [0.55, 3.46] |
| 3 Objectve measurement of incontinence Show forest plot | 2 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 3.1 Bottom‐up approach | 2 | 188 | Risk Ratio (M‐H, Fixed, 95% CI) | 4.44 [2.06, 9.56] |
| 4 Condition‐specific health measures Show forest plot | 1 | Mean Difference (IV, Fixed, 95% CI) | Totals not selected | |
| 4.1 Bottom‐up approach | 1 | Mean Difference (IV, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 5 Duration of operation (in minutes) Show forest plot | 3 | Mean Difference (IV, Random, 95% CI) | Subtotals only | |
| 5.1 Bottom‐up approach | 3 | 386 | Mean Difference (IV, Random, 95% CI) | ‐17.33 [‐32.09, ‐2.57] |
| 6 Operative blood loss Show forest plot | 1 | Mean Difference (IV, Fixed, 95% CI) | Totals not selected | |
| 6.1 Bottom‐up approach | 1 | Mean Difference (IV, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 7 Length of in‐patient stay Show forest plot | 1 | Mean Difference (IV, Fixed, 95% CI) | Totals not selected | |
| 7.1 Bottom‐up approach | 1 | Mean Difference (IV, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 8 Major vascular or visceral injury Show forest plot | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | Totals not selected | |
| 8.1 Bottom‐up approach | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 9 Vaginal wall perforation Show forest plot | 2 | Risk Ratio (M‐H, Fixed, 95% CI) | Totals not selected | |
| 9.1 Bottom‐up approach | 2 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 10 Bladder or urethral perforation Show forest plot | 4 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 10.1 Bottom‐up approach | 4 | 532 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.45 [0.15, 1.38] |
| 11 Urinary retention and need for catheterisation Show forest plot | 5 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 11.1 Bottom‐up approach | 5 | 578 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.87 [0.38, 1.99] |
| 12 Infection related to use of synthetic mesh Show forest plot | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 12.1 Bottom‐up approach | 1 | 50 | Risk Ratio (M‐H, Fixed, 95% CI) | 2.0 [0.22, 17.89] |
| 13 Vaginal mesh exposure Show forest plot | 2 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 13.1 Bottom‐up approach | 2 | 333 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.37 [0.23, 8.16] |
| 14 Mesh extrusion into the bladder or urethra Show forest plot | 3 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 14.1 Bottom‐up approach | 3 | 445 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.76 [0.19, 3.01] |
| 15 Long‐term pain or discomfort Show forest plot | 2 | 329 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 15.1 Bottom‐up approach | 2 | 329 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 16 Dyspareunia Show forest plot | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 16.1 Bottom‐up approach | 1 | 59 | Risk Ratio (M‐H, Fixed, 95% CI) | 2.9 [0.32, 26.30] |
| 17 De novo urgency Show forest plot | 3 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 17.1 Bottom‐up approach | 3 | 248 | Risk Ratio (M‐H, Fixed, 95% CI) | 2.39 [1.25, 4.56] |
| 18 New‐onset detrusor overactivity Show forest plot | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 18.1 Bottom‐up approach | 1 | 70 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.89 [0.13, 5.98] |
| 19 Repeat stress incontinence surgery Show forest plot | 2 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 19.1 Bottom‐up approach | 2 | 333 | Risk Ratio (M‐H, Fixed, 95% CI) | 2.34 [0.79, 6.92] |
| 20 Need for any other additional or new surgical procedure to treat complications Show forest plot | 2 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 20.1 Bottom‐up approach | 2 | 333 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.18 [0.29, 4.74] |
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
| 1 Number of women with urinary incontinence Show forest plot | 17 | 1655 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.91 [1.53, 2.39] |
| 1.1 Inside‐out TVTO | 10 | 1053 | Risk Ratio (M‐H, Fixed, 95% CI) | 2.55 [1.94, 3.36] |
| 1.2 Outside‐in TOT | 7 | 602 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.91 [0.60, 1.39] |
| 2 Number of women with no improvement Show forest plot | 5 | 642 | Risk Ratio (M‐H, Fixed, 95% CI) | 2.29 [1.29, 4.06] |
| 2.1 Inside‐out TVT‐O | 4 | 437 | Risk Ratio (M‐H, Fixed, 95% CI) | 4.80 [2.00, 11.55] |
| 2.2 Outside‐in TOT | 1 | 205 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.76 [0.32, 1.82] |
| 3 Objective measurement of incontinence Show forest plot | 12 | 1198 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.88 [1.49, 2.36] |
| 3.1 Inside‐out TVT‐O | 7 | 804 | Risk Ratio (M‐H, Fixed, 95% CI) | 2.91 [2.00, 4.25] |
| 3.2 Outside‐in TOT | 5 | 394 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.18 [0.90, 1.55] |
| 4 Incontinence episodes Show forest plot | 1 | Mean Difference (IV, Fixed, 95% CI) | Totals not selected | |
| 4.1 Outside‐in TOT | 1 | Mean Difference (IV, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 5 Pad test (weights) Show forest plot | 2 | Mean Difference (IV, Fixed, 95% CI) | Subtotals only | |
| 5.1 Outside‐in TOT | 2 | 268 | Mean Difference (IV, Fixed, 95% CI) | ‐1.64 [‐6.24, 2.96] |
| 6 Condition‐specific health measures Show forest plot | 3 | 334 | Std. Mean Difference (IV, Fixed, 95% CI) | 0.16 [‐0.06, 0.38] |
| 6.1 Inside‐out TVTO | 2 | 290 | Std. Mean Difference (IV, Fixed, 95% CI) | 0.07 [‐0.17, 0.30] |
| 6.2 Outside‐in TOT (UDI 6) | 1 | 44 | Std. Mean Difference (IV, Fixed, 95% CI) | 0.91 [0.25, 1.56] |
| 7 Duration of operation (minutes) Show forest plot | 9 | 1176 | Mean Difference (IV, Fixed, 95% CI) | ‐1.17 [‐1.60, ‐0.75] |
| 7.1 Inside‐out TVTO | 6 | 759 | Mean Difference (IV, Fixed, 95% CI) | ‐1.06 [‐1.50, ‐0.61] |
| 7.2 Outside‐in TOT | 3 | 417 | Mean Difference (IV, Fixed, 95% CI) | ‐2.14 [‐3.43, ‐0.84] |
| 8 Operative blood loss (mL) Show forest plot | 2 | Mean Difference (IV, Fixed, 95% CI) | Subtotals only | |
| 8.1 Inside‐out TVTO | 2 | 320 | Mean Difference (IV, Fixed, 95% CI) | 18.79 [3.70, 33.88] |
| 9 Length of in‐patient stay Show forest plot | 1 | Mean Difference (IV, Fixed, 95% CI) | Subtotals only | |
| 9.1 Inside‐out TVTO | 1 | 188 | Mean Difference (IV, Fixed, 95% CI) | ‐0.08 [‐0.33, 0.17] |
| 10 Major vascular or visceral injury Show forest plot | 3 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 10.1 Inside‐out TVT‐O | 3 | 460 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.40 [0.28, 6.89] |
| 11 Bladder or urethral perforation Show forest plot | 9 | 961 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.27 [0.32, 5.02] |
| 11.1 Inside‐out TVT‐O | 5 | 666 | Risk Ratio (M‐H, Fixed, 95% CI) | 2.45 [0.40, 15.09] |
| 11.2 Outside‐in TOT | 4 | 295 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.21 [0.01, 4.99] |
| 12 Vaginal wall perforation Show forest plot | 6 | 788 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.67 [0.41, 6.81] |
| 12.1 Inside‐out TVT‐O | 5 | 715 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.67 [0.41, 6.81] |
| 12.2 Outside‐in TOT | 1 | 73 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 13 Urinary retention and need for catheterisation Show forest plot | 15 | 1477 | Risk Ratio (M‐H, Random, 95% CI) | 0.57 [0.28, 1.15] |
| 13.1 Inside‐out TVTO | 10 | 996 | Risk Ratio (M‐H, Random, 95% CI) | 0.72 [0.34, 1.52] |
| 13.2 Outside‐in TOT | 5 | 481 | Risk Ratio (M‐H, Random, 95% CI) | 0.51 [0.08, 3.44] |
| 14 Infection related to use of synthetic mesh Show forest plot | 2 | 412 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.49 [0.09, 2.69] |
| 14.1 Inside‐out TVT‐O | 1 | 188 | Risk Ratio (M‐H, Fixed, 95% CI) | 2.88 [0.12, 69.72] |
| 14.2 Outside‐in TOT | 1 | 224 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.14 [0.01, 2.73] |
| 15 Vaginal mesh exposure Show forest plot | 9 | 819 | Risk Ratio (M‐H, Fixed, 95% CI) | 2.59 [1.21, 5.56] |
| 15.1 Inside‐out TVT‐O | 5 | 562 | Risk Ratio (M‐H, Fixed, 95% CI) | 3.75 [1.42, 9.86] |
| 15.2 Outside‐in TOT | 4 | 257 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.07 [0.27, 4.28] |
| 16 Mesh extrusion into the bladder or urethra Show forest plot | 2 | 146 | Risk Ratio (M‐H, Fixed, 95% CI) | 17.79 [1.06, 298.88] |
| 16.1 Inside‐out TVT‐O | 1 | 86 | Risk Ratio (M‐H, Fixed, 95% CI) | 17.79 [1.06, 298.88] |
| 16.2 Outside‐in TOT | 1 | 60 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 17 Postoperative pain or discomfort Show forest plot | 9 | 1102 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.26 [0.19, 0.37] |
| 17.1 Inside‐out TVTO | 8 | 806 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.29 [0.20, 0.43] |
| 17.2 Outside‐in TOT | 2 | 296 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.19 [0.09, 0.40] |
| 18 Long‐term pain or discomfort Show forest plot | 5 | 351 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.14 [0.04, 0.54] |
| 18.1 Inside‐out TVT‐O | 3 | 235 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.17 [0.03, 1.07] |
| 18.2 Outside‐in TOT | 2 | 116 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.12 [0.02, 0.82] |
| 19 De novo urgency Show forest plot | 10 | 927 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.41 [0.98, 2.03] |
| 19.1 Inside‐out TVT‐O | 8 | 835 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.31 [0.90, 1.90] |
| 19.2 Outside‐in TOT | 2 | 92 | Risk Ratio (M‐H, Fixed, 95% CI) | 5.15 [0.68, 39.23] |
| 20 Repeat stress incontinence surgery Show forest plot | 6 | 764 | Risk Ratio (M‐H, Fixed, 95% CI) | 3.09 [1.48, 6.49] |
| 20.1 Inside‐out TVT‐O | 3 | 420 | Risk Ratio (M‐H, Fixed, 95% CI) | 5.86 [2.00, 17.21] |
| 20.2 Outside‐in TOT | 3 | 344 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.0 [0.31, 3.18] |
| 21 Need for any other additional or new surgical procedure to treat complications Show forest plot | 8 | 989 | Risk Ratio (M‐H, Fixed, 95% CI) | 2.03 [1.09, 3.78] |
| 21.1 Inside‐out TVT‐O | 5 | 645 | Risk Ratio (M‐H, Fixed, 95% CI) | 2.15 [1.04, 4.43] |
| 21.2 Outside‐in TOT | 3 | 344 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.75 [0.52, 5.85] |
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
| 1 Number of women with urinary incontinence Show forest plot | 6 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 1.1 TVT‐SECUR versus MiniArc | 2 | 170 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.11 [0.95, 1.29] |
| 1.2 U‐type versus H‐type TVT‐Secur | 3 | 496 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.04 [0.78, 1.40] |
| 1.3 MiniArc versus Ajust | 1 | 63 | Risk Ratio (M‐H, Fixed, 95% CI) | 2.91 [0.63, 13.32] |
| 2 Number of women with no improvement Show forest plot | 4 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 2.1 TVT‐Secur versus MiniArc | 2 | 170 | Risk Ratio (M‐H, Fixed, 95% CI) | 3.25 [0.84, 12.66] |
| 2.2 U‐type versus H‐type TVT‐Secur | 1 | 129 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.74 [0.33, 1.63] |
| 2.3 MiniArc versus Ajust | 1 | 61 | Risk Ratio (M‐H, Fixed, 95% CI) | 2.21 [0.21, 23.08] |
| 3 Objectve measurement of incontinence Show forest plot | 4 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 3.1 MiniArc versus Ajust | 1 | 63 | Risk Ratio (M‐H, Fixed, 95% CI) | 2.91 [0.63, 13.32] |
| 3.2 U‐type versus H‐type TVT‐Secur | 3 | 496 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.77 [0.56, 1.07] |
| 4 Condition‐specific health measures Show forest plot | 3 | Mean Difference (IV, Fixed, 95% CI) | Subtotals only | |
| 4.1 MiniArc versus AJUST | 1 | 60 | Mean Difference (IV, Fixed, 95% CI) | ‐0.13 [‐1.58, 1.32] |
| 4.2 U‐type versus H‐type TVT‐Secur | 2 | 414 | Mean Difference (IV, Fixed, 95% CI) | ‐0.30 [‐2.15, 1.55] |
| 5 Duration of operation (minutes) Show forest plot | 2 | Mean Difference (IV, Fixed, 95% CI) | Subtotals only | |
| 5.1 TVT‐Secur versus MiniArc | 2 | 190 | Mean Difference (IV, Fixed, 95% CI) | 1.70 [‐4.11, 7.51] |
| 5.2 Ajust versus MiniArc | 1 | 80 | Mean Difference (IV, Fixed, 95% CI) | 1.20 [‐4.67, 7.07] |
| 6 Operative blood loss Show forest plot | 3 | Mean Difference (IV, Fixed, 95% CI) | Subtotals only | |
| 6.1 U‐type versus H‐type TVT‐Secur | 2 | 459 | Mean Difference (IV, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 6.2 Ajust versus MiniArc | 1 | 80 | Mean Difference (IV, Fixed, 95% CI) | ‐1.20 [‐10.04, 7.64] |
| 6.3 TVT‐Secur versus MiniArc | 1 | 80 | Mean Difference (IV, Fixed, 95% CI) | 4.30 [‐5.53, 14.13] |
| 7 Major vascular or visceral injury Show forest plot | 2 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 7.1 U‐type versus H‐type TVT‐Secur | 2 | 459 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.25 [0.03, 2.19] |
| 8 Bladder or urethral perforation Show forest plot | 3 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 8.1 U‐type versus H‐type TVT‐Secur | 2 | 459 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.33 [0.01, 7.91] |
| 8.2 TVT‐Secur versus MiniArc | 1 | 110 | Risk Ratio (M‐H, Fixed, 95% CI) | 4.18 [0.21, 85.11] |
| 9 Vaginal wall perforation Show forest plot | 2 | Risk Ratio (M‐H, Fixed, 95% CI) | Totals not selected | |
| 9.1 TVT‐S versus MiniArc | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 9.2 U‐type versus H‐type TVT‐Secur | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 10 Urinary retention and need for catheterisation Show forest plot | 4 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 10.1 TVT‐Secur versus MiniArc | 3 | 250 | Risk Ratio (M‐H, Fixed, 95% CI) | 2.05 [0.47, 8.95] |
| 10.2 U‐type versus H‐type TVT‐Secur | 1 | 330 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.67 [0.11, 3.94] |
| 10.3 Ajust versus MiniArc | 1 | 80 | Risk Ratio (M‐H, Fixed, 95% CI) | 5.0 [0.25, 100.97] |
| 11 Vaginal mesh exposure Show forest plot | 2 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 11.1 U‐type versus H‐type TVT‐Secur | 2 | 414 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.79 [0.22, 2.80] |
| 12 Postoperative pain or discomfort Show forest plot | 1 | Mean Difference (IV, Fixed, 95% CI) | Totals not selected | |
| 12.1 Ajust versus MiniArc | 1 | Mean Difference (IV, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 12.2 TVT‐Secur versus MiniArc | 1 | Mean Difference (IV, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 13 De novo urgency Show forest plot | 5 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 13.1 TVT‐Secur versus MiniArc | 3 | 250 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.69 [0.24, 2.02] |
| 13.2 U‐type versus H‐type TVT‐Secur | 2 | 367 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.09 [0.53, 2.25] |
| 13.3 Ajust versus MiniArc | 1 | 80 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.5 [0.26, 8.50] |
| 14 Repeat stress incontinence surgery Show forest plot | 2 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 14.1 U‐type versus H‐type TVT‐Secur | 2 | 414 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.16 [0.54, 2.51] |
| 15 Need for any other additional or new surgical procedure to treat complications Show forest plot | 3 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 15.1 U‐type versus H‐type TVT‐Secur | 2 | 414 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.27 [0.04, 1.61] |
| 15.2 TVT‐Secur vs Mini‐Arc | 1 | 110 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.67 [0.16, 17.85] |
